Oncology-focused Revolution Medicines has initiated a multi-year collaboration with AI drug discovery firm Iambic Therapeutics worth up to $25 million. Iambic will train its NeuralPLexer protein-ligand structure prediction AI platform using Revolution’s proprietary molecular libraries and structural data to identify novel drug candidates against difficult oncology targets. The deal also grants Revolution use rights to Iambic’s PropANE model for lead selection and optimization. Both parties retain rights to a limited number of exclusive targets, ensuring focused discovery efforts. Revolution CEO Mark Goldsmith highlighted that AI-powered exploration of RAS-addicted cancers may accelerate identification of therapeutics beyond conventional approaches. The collaboration underscores growing integration of machine learning and physics-based methods in drug discovery pipelines.